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Abstract
Introduction: Cardiovascular disease (CVD) is a major 
cause of morbidity and mortality in chronic kidney patients 
(CKD). The aim of this study was to demonstrate the role 
of soluble tumor necrosis factor (TNF) weak inducer 
of apoptosis (sTWEAK) as a marker of cardiovascular 
morbidity and mortality in CKD patients.
Methods:  The study included 75 CKD patients classified 
according to eGFR into three groups; group-1 included 15 
patients with stage-1 CKD, group-2 included 30 patients 
with stage-2 and stage-3 CKD, and group-3 included 30 
patients with stage-4 and stage-5 CKD. The three groups 
were compared to 20 matched controls. Interleukin-6 
(IL-6) and sTWEAK were measured using ELISA and 
chemiluminescent techniques respectively. Carotid 
intima-media thickness (IMT) was also measured.
Results: We found that IL-6 showed significant difference 
between patient groups and controls, being highest 
in stage 4 and 5 CKD patients and lowest in controls. 
Soluble TWEAK showed significant difference between 
patient groups and controls, being lowest in stage 4 and 
5 CKD patients and highest in controls. Soluble TWEAK 
level showed significant negative correlation with IL-6 
(r = -0.68; P<0.01) and carotid IMT (r = -0.95; P<0.01). 
After two years follow up, nine out of 75 CKD patients 
developed ischemic heart disease (IHD). Two patients 
developed cerebrovascular stroke and another patient 
developed peripheral arterial disease. These patients 
had significantly lower levels of sTWEAK at baseline 
compared to other patients (160.5± 60.2 versus 274.8±90 
pg/mL; P < 0.05).
Conclusion: Soluble TWEAK can be a novel biomarker 
of atherosclerosis and endothelial dysfunction as well as 
cardiovascular outcome in CKD patients.
KeyWords: Cardiovascular morbidity; Cardiovascular 
mortality; CVD; IL-6; TWEAK
Introduction
Cardiovascular disease (CVD) represents a major cause 
of morbidity and mortality in chronic kidney disease 
patients (CKD) [1]. The progression to end stage renal 
disease (ESRD) is associated with increased incidence of 
adverse cardiovascular outcomes, which is responsible 
for increased mortality of CKD patients more than the 
progression of chronic kidney disease itself [2]. The 
mechanisms for the elevated CVD risk in CKD patients 
are complex and may involve changes in the heart and 
vasculature at earlier stages [3]. Hypertension, diabetes 
mellitus, dyslipidaemia, and premature atherosclerosis 
are major contributors to cardiovascular morbidity 
in CKD patients [4]. Endothelial dysfunction (ED) is 
the initial pathophysiologic step in the progression of 
vascular damage and premature atherosclerosis that 
precedes and leads to clinically manifest cardiovascular 
diseases [5]. ED is highly prevalent in patients with 
moderate to advanced chronic kidney disease and is 
linked to the elevated cardiovascular risk of this patient 
population [6]. The cause of ED is complex and involves 
dysregulation of multiple pathways. One of those 
could be mediated by the TNF-like weak inducer of 
apoptosis (TWEAK), a member of the TNF superfamily 
of cytokines [7]. TWEAK is a type II transmembrane 
glycoprotein (30 kD) that circulates in plasma in a soluble 
form (sTWEAK) with a molecular weight of 18 kD. 
Soluble TWEAK is generated by proteolytic cleavage of 
TWEAK, which is a member of the TNF super-family. 
In humans, TWEAK mRNA expression is abundant in 
a wide variety of tissues [8]. Soluble TWEAK increases 
the expression and secretion of various proteins involved 
in the inflammatory response, including prostaglandin 
E2; matrix metalloproteinase 1; IL-6 and IL-8 [9]. IL-6 
is an inflammatory cytokine, which is secreted by a 
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variety of different cell types, including lymphoid and 
endothelial cells, fibroblasts, skeletal muscle, and adipose 
tissue. Circulating IL-6 levels correlate with premature 
atherosclerosis and ED [10].
TWEAK is widely expressed and can be found in 
pancreas, intestine, heart, brain, lung, ovary, the 
vasculature, skeletal muscle, liver, and kidney. Binding of 
TWEAK to its receptor, fibroblast growth factor inducible 
14(Fn14), mediates multiple biologic effects such as 
cellular proliferation, migration, survival, differentiation, 
osteoclastogenesis, angiogenesis, and apoptosis [11]. In 
addition, TWEAK/Fn14 interactions have also been found 
to induce inflammation as they up regulate a number of 
chemokines, cytokines and adhesion molecules in various 
tissues [12]. While TWEAK and Fn14 genes are widely 
expressed, their expression level is dramatically elevated 
in the context of acute injury and disease [13]. Currently 
it is thought that TWEAK facilitates physiologic tissue 
repair and regeneration following acute injury, but in the 
setting of chronic inflammatory diseases the irregular 
expression of TWEAK is pathogenic [14].
Methods
This study included 75 patients, who were diagnosed as 
having CKD according to their estimated GFR (eGFR) 
and the presence of kidney injury as defined by National 
Kidney Foundation Kidney Disease Outcomes Quality 
Initiative Guidelines. Group-1included 15 patients who 
had stage 1 CKD, Group-2 included 30 patients who had 
stage 2 and  3 CKD, Group-3 included 30 patients who 
had stage 4 and 5 CKD. These groups were compared 
with 20 controls matched in age, sex and body mass 
index (BMI) with the 3 groups of patients. The patients 
were recruited from the outpatient clinic of nephrology, 
Cairo University and Cairo University hospitals. This 
study was performed from January 2008 to December 
2010.
Exclusion Criteria were: the presence of ischemic heart 
disease (IHD) at initial presentation, the presence of 
diabetes mellitus and current smoking. All patients 
were subjected to complete history taking and clinical 
examination, measurement of BMI, and laboratory 
measurements. Seven milliliters of blood were drawn 
from each patient after fasting for 12 hours, distributed 
and aliquoted. Hemoglobin was measured using an 
EDTA tube. Two serum aliquots were frozen at -20C 
for the analysis of TWEAK and IL6. One serum 
aliquot was immediately used for the determination of 
total cholesterol (TC), triglycerides (TGD), calcium, 
phosphorus, albumin and serum creatinine. Estimated 
GFR was calculated according to the Modification of 
Diet in Renal Disease formula (MDRD) as defined by 
Levey et al [15]. Interleukin (IL-6) assay was done 
with a solid-phase, enzyme-labeled, chemiluminescent 
sequential immunometric assay (Immulite 2000; DPC 
DIPESA S.A., Madrid, Spain)[16]. Serum concentrations 
of sTWEAK were determined with a sandwich ELISA 
technique (Bender Med Systems, Vienna, Austria) 
[17], where sTWEAK was sandwiched between an 
anti-TWEAK polyclonal coating antibody and a biotin-
conjugated polyclonal anti-TWEAK antibody. Twenty-
four hour urinary protein measurements were performed 
at baseline. ECG and echocardiography were performed 
at the start of the study and after two years follow up. 
Carotid intima media thickness was measured using a 
high resolution scanning device.
Analysis of data was done using SPSS (version 12). 
Values were expressed as means ± SD. Unpaired t-test 
and one way ANOVA were used to compare two or more 
groups, respectively. Correlation coefficient was used 
to rank variables against each other. P value <0.05 was 
considered significant.
Results
Table-1 summarizes the demographic and clinical data of 
the patients in the three study groups. All the three groups 
were comparable in these respects. Table-2 compares 
the laboratory data obtained in the three study groups. 
As expected Group-3 patients (CKD-4 and CKD-5) had 
significantly lower mean serum calcium, lower mean 
hemoglobin and higher mean serum phosphorus levels 
compared to Group-1 patients (CKD-1). The mean 
carotid IMT was significantly higher in Groups 3 and 
4 compared to Group-1 patients. The mean sTWEAK 
levels were significantly higher in the control group 
compared to patients in groups 2 and 3, while IL-6 levels 
were significantly lower in the control group compared 
to all the three test groups (Table-3).
Soluble TWEAK had statistically-significant negative 
correlation with systolic blood pressure (r = -0.82; 
P<0.01), diastolic blood pressure (r = -0.71; P<0.01), age 
(r = -0.75; P<0.01), TC (r = -0.56; P<0.01), TGD levels 
(r = -0.40; P<0.05), BMI (r = -0.66; P<0.01), carotid 
IMT (r = -0.95; P<0.01) and IL-6 (r = -0.68; P<0.01). No 
significant correlation was found with serum calcium, 
serum phosphorus, hemoglobin levels, serum albumin, 
or the degree of proteinuria (P>0.05).
After two years of follow up, nine CKD patients out of 
75 developed IHD, two of whom died from myocardial 
infarction. Two patients developed cerebrovascular 
stroke and another patient developed peripheral arterial 
disease. These patients had significantly lower level of 
sTWEAK (160.5± 60.2 pg/mL) at baseline compared to 
other patients (274.8±90 pg/mL).
Table 1: Demographic and clinical data of studied CKD patients 
Variable Group 1 Group 2 Group 3 P value
Age 49.6±6.1 49.8±3.3 51±6.4 >0.05
Gender (males/females) 12/3 25/5 26/4 >0.05
Systolic blood pressure* 133.5±6 134±8.3 135.4±9 >0.05
Diastolic blood pressure 85±4.5 85.9±6.3 86.9±6 >0.05
BMI (kg/m2) 27.2±1.8 26.4±2.1 25.5±1.5 >0.05
Etiology of CKD
 >0.05Glomerulonephritis 4 9 10
Interstitial nephritis 4 7 6
ADPKD** 3 6 4
Hypertension 4 7 7
Unknown 0 1 3
* Blood pressure was controlled by angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, 
or centrally acting antihypertensives.
**Autosomal dominant polycyctic kidney disease.
Discussion
Chronic kidney disease (CKD) is strongly associated 
with cardiovascular disease (CVD), which  may account 
for 50% of all deaths in this patient population [18]. 
Irrespective of the cause of renal disease, there is firm 
evidence that a chronic proinflammatory state and 
progressive atherosclerosis coexist in patients with CKD 
and that inflammation contributes to cardiovascular 
morbidity and mortality [19]. This inflammatory 
phenomenon is frequently observed even before the 
initiation of renal replacement therapy [20]. In recent 
years, a number of new circulating biomarkers of 
atherosclerosis-associated cardiovascular risk have been 
identified in the general population.
Blanco-Colio et al [21] suggested that sTWEAK is one of 
the potential novel biomarkers of atherosclerosis. In this 
study, we measured sTWEAK and IL-6 level in patients 
with different stages of CKD and controls, and we found 
that sTWEAK was significantly different between groups, 
being lowest in stage 4 and 5 CKD patients, and highest 
in controls. IL-6 was also significantly different between 
groups, being highest in stage 4 and 5 CKD patients, and 
lowest in controls.
Yilmaz et al [22] measured sTWEAK in non-dialysis 
CKD patients and found that sTWEAK gradually 
decreased parallel to increased CKD stages and this 
decrease was parallel to the reduction in eGFR. Also, 
Meier et al [23] reported that sTWEAK plasma levels 
decrease with impaired renal function and are associated 
with the aggravation of the endothelial dysfunction and 
the mortality risk. In this study, we found that sTWEAK 
had significant negative correlation with both systolic 
and diastolic BP, age, TC, TGD levels, BMI, carotid IMT, 
and IL-6. These data suggest that sTWEAK may play a 
role in endothelial dysfunction (ED) and atherogenesis, 
being inversely correlated with traditional atherogenic 
risk factors and an inflammatory cytokine (IL6) that 
plays an important role in ED and atherosclerosis. It is 
also indicated in this study that sTWEAK can predict 
cardiovascular outcome in CKD patients as it had strong 
negative correlation with carotid IMT and the patients 
who developed IHD on follow up had significantly 
lower levels of sTWEAK at baseline. Yilmaz et al 
[22] also reported that sTWEAK can be a marker of 
cardiovascular outcome in CKD patients. Although 
carrero et al [3] also found a reduction in sTWEAK 
levels in CKD patients compared to healthy controls, 
their observations contradicted with our findings in that 
the worst prognosis was for those with high sTWEAK 
levels. This contradiction may be due to the different type 
of studied patients, as their study was conducted on HD 
patients with more prominent fluctuations in their clinical 
conditions and surely, biochemical markers. 
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variety of different cell types, including lymphoid and 
endothelial cells, fibroblasts, skeletal muscle, and adipose 
tissue. Circulating IL-6 levels correlate with premature 
atherosclerosis and ED [10].
TWEAK is widely expressed and can be found in 
pancreas, intestine, heart, brain, lung, ovary, the 
vasculature, skeletal muscle, liver, and kidney. Binding of 
TWEAK to its receptor, fibroblast growth factor inducible 
14(Fn14), mediates multiple biologic effects such as 
cellular proliferation, migration, survival, differentiation, 
osteoclastogenesis, angiogenesis, and apoptosis [11]. In 
addition, TWEAK/Fn14 interactions have also been found 
to induce inflammation as they up regulate a number of 
chemokines, cytokines and adhesion molecules in various 
tissues [12]. While TWEAK and Fn14 genes are widely 
expressed, their expression level is dramatically elevated 
in the context of acute injury and disease [13]. Currently 
it is thought that TWEAK facilitates physiologic tissue 
repair and regeneration following acute injury, but in the 
setting of chronic inflammatory diseases the irregular 
expression of TWEAK is pathogenic [14].
Methods
This study included 75 patients, who were diagnosed as 
having CKD according to their estimated GFR (eGFR) 
and the presence of kidney injury as defined by National 
Kidney Foundation Kidney Disease Outcomes Quality 
Initiative Guidelines. Group-1included 15 patients who 
had stage 1 CKD, Group-2 included 30 patients who had 
stage 2 and  3 CKD, Group-3 included 30 patients who 
had stage 4 and 5 CKD. These groups were compared 
with 20 controls matched in age, sex and body mass 
index (BMI) with the 3 groups of patients. The patients 
were recruited from the outpatient clinic of nephrology, 
Cairo University and Cairo University hospitals. This 
study was performed from January 2008 to December 
2010.
Exclusion Criteria were: the presence of ischemic heart 
disease (IHD) at initial presentation, the presence of 
diabetes mellitus and current smoking. All patients 
were subjected to complete history taking and clinical 
examination, measurement of BMI, and laboratory 
measurements. Seven milliliters of blood were drawn 
from each patient after fasting for 12 hours, distributed 
and aliquoted. Hemoglobin was measured using an 
EDTA tube. Two serum aliquots were frozen at -20C 
for the analysis of TWEAK and IL6. One serum 
aliquot was immediately used for the determination of 
total cholesterol (TC), triglycerides (TGD), calcium, 
phosphorus, albumin and serum creatinine. Estimated 
GFR was calculated according to the Modification of 
Diet in Renal Disease formula (MDRD) as defined by 
Levey et al [15]. Interleukin (IL-6) assay was done 
with a solid-phase, enzyme-labeled, chemiluminescent 
sequential immunometric assay (Immulite 2000; DPC 
DIPESA S.A., Madrid, Spain)[16]. Serum concentrations 
of sTWEAK were determined with a sandwich ELISA 
technique (Bender Med Systems, Vienna, Austria) 
[17], where sTWEAK was sandwiched between an 
anti-TWEAK polyclonal coating antibody and a biotin-
conjugated polyclonal anti-TWEAK antibody. Twenty-
four hour urinary protein measurements were performed 
at baseline. ECG and echocardiography were performed 
at the start of the study and after two years follow up. 
Carotid intima media thickness was measured using a 
high resolution scanning device.
Analysis of data was done using SPSS (version 12). 
Values were expressed as means ± SD. Unpaired t-test 
and one way ANOVA were used to compare two or more 
groups, respectively. Correlation coefficient was used 
to rank variables against each other. P value <0.05 was 
considered significant.
Results
Table-1 summarizes the demographic and clinical data of 
the patients in the three study groups. All the three groups 
were comparable in these respects. Table-2 compares 
the laboratory data obtained in the three study groups. 
As expected Group-3 patients (CKD-4 and CKD-5) had 
significantly lower mean serum calcium, lower mean 
hemoglobin and higher mean serum phosphorus levels 
compared to Group-1 patients (CKD-1). The mean 
carotid IMT was significantly higher in Groups 3 and 
4 compared to Group-1 patients. The mean sTWEAK 
levels were significantly higher in the control group 
compared to patients in groups 2 and 3, while IL-6 levels 
were significantly lower in the control group compared 
to all the three test groups (Table-3).
Soluble TWEAK had statistically-significant negative 
correlation with systolic blood pressure (r = -0.82; 
P<0.01), diastolic blood pressure (r = -0.71; P<0.01), age 
(r = -0.75; P<0.01), TC (r = -0.56; P<0.01), TGD levels 
(r = -0.40; P<0.05), BMI (r = -0.66; P<0.01), carotid 
IMT (r = -0.95; P<0.01) and IL-6 (r = -0.68; P<0.01). No 
significant correlation was found with serum calcium, 
serum phosphorus, hemoglobin levels, serum albumin, 
or the degree of proteinuria (P>0.05).
After two years of follow up, nine CKD patients out of 
75 developed IHD, two of whom died from myocardial 
infarction. Two patients developed cerebrovascular 
stroke and another patient developed peripheral arterial 
disease. These patients had significantly lower level of 
sTWEAK (160.5± 60.2 pg/mL) at baseline compared to 
other patients (274.8±90 pg/mL).
Table 1: Demographic and clinical data of studied CKD patients 
Variable Group 1 Group 2 Group 3 P value
Age 49.6±6.1 49.8±3.3 51±6.4 >0.05
Gender (males/females) 12/3 25/5 26/4 >0.05
Systolic blood pressure* 133.5±6 134±8.3 135.4±9 >0.05
Diastolic blood pressure 85±4.5 85.9±6.3 86.9±6 >0.05
BMI (kg/m2) 27.2±1.8 26.4±2.1 25.5±1.5 >0.05
Etiology of CKD
 >0.05Glomerulonephritis 4 9 10
Interstitial nephritis 4 7 6
ADPKD** 3 6 4
Hypertension 4 7 7
Unknown 0 1 3
* Blood pressure was controlled by angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, 
or centrally acting antihypertensives.
**Autosomal dominant polycyctic kidney disease.
Discussion
Chronic kidney disease (CKD) is strongly associated 
with cardiovascular disease (CVD), which  may account 
for 50% of all deaths in this patient population [18]. 
Irrespective of the cause of renal disease, there is firm 
evidence that a chronic proinflammatory state and 
progressive atherosclerosis coexist in patients with CKD 
and that inflammation contributes to cardiovascular 
morbidity and mortality [19]. This inflammatory 
phenomenon is frequently observed even before the 
initiation of renal replacement therapy [20]. In recent 
years, a number of new circulating biomarkers of 
atherosclerosis-associated cardiovascular risk have been 
identified in the general population.
Blanco-Colio et al [21] suggested that sTWEAK is one of 
the potential novel biomarkers of atherosclerosis. In this 
study, we measured sTWEAK and IL-6 level in patients 
with different stages of CKD and controls, and we found 
that sTWEAK was significantly different between groups, 
being lowest in stage 4 and 5 CKD patients, and highest 
in controls. IL-6 was also significantly different between 
groups, being highest in stage 4 and 5 CKD patients, and 
lowest in controls.
Yilmaz et al [22] measured sTWEAK in non-dialysis 
CKD patients and found that sTWEAK gradually 
decreased parallel to increased CKD stages and this 
decrease was parallel to the reduction in eGFR. Also, 
Meier et al [23] reported that sTWEAK plasma levels 
decrease with impaired renal function and are associated 
with the aggravation of the endothelial dysfunction and 
the mortality risk. In this study, we found that sTWEAK 
had significant negative correlation with both systolic 
and diastolic BP, age, TC, TGD levels, BMI, carotid IMT, 
and IL-6. These data suggest that sTWEAK may play a 
role in endothelial dysfunction (ED) and atherogenesis, 
being inversely correlated with traditional atherogenic 
risk factors and an inflammatory cytokine (IL6) that 
plays an important role in ED and atherosclerosis. It is 
also indicated in this study that sTWEAK can predict 
cardiovascular outcome in CKD patients as it had strong 
negative correlation with carotid IMT and the patients 
who developed IHD on follow up had significantly 
lower levels of sTWEAK at baseline. Yilmaz et al 
[22] also reported that sTWEAK can be a marker of 
cardiovascular outcome in CKD patients. Although 
carrero et al [3] also found a reduction in sTWEAK 
levels in CKD patients compared to healthy controls, 
their observations contradicted with our findings in that 
the worst prognosis was for those with high sTWEAK 
levels. This contradiction may be due to the different type 
of studied patients, as their study was conducted on HD 
patients with more prominent fluctuations in their clinical 
conditions and surely, biochemical markers. 
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Blanco-Colio et al [21] analyzed supernatants obtained 
from cultured human carotid plaques and healthy arteries 
and found that sTWEAK levels were decreased in 
carotid plaque supernatants. Subsequent measurement 
of sTWEAK in plasma showed a reduced concentration 
in subjects with carotid stenosis compared with healthy 
subjects. Furthermore, they found that sTWEAK 
concentrations were negatively correlated with the carotid 
intima-media thickness in asymptomatic subjects, and 
reported that sTWEAK can be an index of subclinical 
atherosclerosis.
Studies are directed towards the discovery of the cause 
of decreased sTWEAK levels as a provoking factor 
of atherogenesis. It was found that in animal models 
the pathologic effects of sTWEAK were mediated by 
the binding with its receptor Fn14. Fn14 expression is 
practically absent in healthy human aortic wall but is 
highly increased under pathologic conditions. A pro-
inflammatory environment increases Fn14 expression, and 
also  allows CD163 to sequester and degrade sTWEAK 
by acting as a scavenger receptor, thus preventing Fn14 
binding [24]. 
On the basis of these explanations we can speculate 
that the reduction in sTWEAK concentrations across 
CKD stages could potentially reflect either of these two 
processes. King [25] reported that administration of 
TWEAK in experimental animals resulted in formation of 
extensive atherosclerotic lesions, which were prevented 
by pretreatment with anti-TWEAK antibody. Muñoz-
García et al [26] also reported that in experimental mice, 
administration of TWEAK aggravated macrophage and 
chemokine expression in atherosclerotic plaques and in 
renal lesions.
A possible explanation of this apparent contradiction is 
that endogenous TWEAK participates in the atherogenic 
process.  Recent data suggest that TWEAK is also a 
ligand for the scavenger receptor, CD163. Differences 
observed between studies could be attributed to TWEAK/
CD163-mediated effects, suggesting that TWEAK may 
mediate some of its effects through receptors other than 
Fn14 [25]. 
Conclusion
Soluble TWEAK levels are significantly lower in CKD 
patients compared to controls. Soluble TWEAK can be 
a novel biomarker of atherosclerosis and endothelial 
dysfunction as well as cardiovascular outcome in CKD 
patients.
Table 2: Laboratory data and carotid intima media thickness (IMT) of studied CKD patients
Variable Group 1 Group 2 Group 3 P value
Total cholesterol (mg/dL) 188±23.5 190.5±28 188.6±33.7 >0.05
Triglycerides (mg/dL) 156.4±13.5 157±13.2 157±11 >0.05
Serum calcium (mg/dL) 9.9±0.5 8.2±0.6 7.2±0.8 <0.01
Serum phosphorus (mg/dL) 4.5±0.4 5.9±0.7 6.8±1.4 <0.01
Serum albumin (g/dL) 3.8±0.2 3.7±0.3 3.9±0.1 >0.05
24 hours urinary proteins (g/day) 1.5±0.5 1.1±0.3 0.7±0.3 <0.01
Hemoglobin (g/dL) 13.5±1.4 11.2±1 8.9±0.9 <0.01
Carotid IMT (mm) 0.5±0.01 0.71±0.06 0.92±0.1 <0.01
Table 3: sTWEAK and IL-6 level in studied CKD patients and controls
Variable Group 1 Group 2 Group 3 Controls P value
sTWEAK(pg/mL) 380.2±50.5 290.6±50.8 160.8±70.8 450±64.4 <0.01
IL-6(pg/mL) 4.2±1.8 7.1±2 11±2.1 2.1±1 <0.01
References
1. Shamseddin MK, Parfrey PS. Sudden cardiac death 
in chronic kidney disease: epidemiology and prevention. 
Nat Rev Nephrol. 2011 Mar;7(3):145-54.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu 
CY. Chronic kidney disease and the risks of death, 
cardiovascular events, and hospitalization. N Engl J Med. 
2004 Sep 23;351(13):1296-305. 
3. Carrero JJ, Stenvinkel P. Inflammation in end-stage 
renal disease = what have we learned in 10 years? Semin 
Dial. 2010 Sep-Oct;23(5):498-509.
4. Dasmahapatra P, Srinivasan SR, Mokha J, Fernandez C, 
Chen W, Xu J, Berenson GS. Subclinical atherosclerotic 
changes related to chronic kidney disease in asymptomatic 
black and white young adults: the Bogalusa heart study. 
Ann Epidemiol. 2011 May;21(5):311-7.
5. Libby P, Ridker PM, Maseri A. Inflammation and 
atherosclerosis. Circulation. 2002 Mar 5;105(9):1135-
43.
6. Endemann DH, Sciffrin EL. Endothelial dysfunction. J 
Am Soc Nephrol. 2004 Aug;15(8):1983-92.
7. Winkles JA. The TWEAK-Fn14 cytokine-receptor 
axis: discovery, biology and therapeutic targeting. Nat 
Rev Drug Discov. 2008 May;7(5):411-25.
8. Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, 
Lössner U, Blüher M, Stumvoll M, Fasshauer M. Serum 
levels of the atherosclerosis biomarker sTWEAK are 
decreased in type 2 diabetes and end-stage renal disease. 
Atherosclerosis. 2008 Aug;199(2):440-4. 
9. Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, 
Bárány P, Heimbürger O, Marrón B, Metry G, Snaedal 
S, Lindholm B, Egido J, Stenvinkel P, Blanco-Colio LM. 
Additive effects of soluble TWEAK and inflammation 
on mortality in hemodialysis patients. Clin J Am Soc 
Nephrol. 2009 Jan;4(1):110-8. 
10. Vila E, Salaices M. Cytokines and vascular reactivity 
in resistance arteries. Am J Physiol Heart Circ Physiol. 
2005 Mar;288(3):H1016-21.
11. Polek TC, Talpaz M, Darnay BG, Spivak-Kroizman T. 
TWEAK mediates signal transduction and differentiation 
of RAW264.7 cells in the absence of Fn14/TweakR. 
Evidence for a second TWEAK receptor. J Biol Chem. 
2003 Aug 22;278(34):32317-23.
12. Kim SH, Kang YJ, Kim WJ, Woo DK, Lee Y, Kim 
DI, Park YB, Kwon BS, Park JE, Lee WH. TWEAK 
can induce pro-inflammatory cytokines and matrix 
metalloproteinase-9 in macrophages. Circ J. 2004 
Apr;68(4):396-9.
13. Sanz AB, Justo P, Sanchez-Niño MD, Blanco-Colio 
LM, Winkles JA, Kreztler M, Jakubowski A, Blanco J, 
Egido J, Ruiz-Ortega M, Ortiz A. The cytokine TWEAK 
modulates renal tubulointerstitial inflammation. J Am 
Soc Nephrol. 2008 Apr;19(4):695-703. 
14. Muñoz-García B, Martín-Ventura JL, Martínez E, 
Sánchez S, Hernández G, Ortega L, Ortiz A, Egido J, 
Blanco-Colio LM. Fn14 is upregulated in cytokine-
stimulated vascular smooth muscle cells and is expressed 
in human carotid atherosclerotic plaques: modulation by 
atorvastatin. Stroke. 2006 Aug;37(8):2044-53. 
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, 
Roth D. A more accurate method to estimate glomerular 
filtration rate from serum creatinine: a new prediction 
equation. Modification of Diet in Renal Disease Study 
Group. Ann Intern Med. 1999 Mar 16;130(6):461-70.
16. Esteve E, Castro A, López-Bermejo A, Vendrell 
J, Ricart W, Fernández-Real JM. Serum interleukin-6 
correlates with endothelial dysfunction in healthy men 
independently of insulin sensitivity. Diabetes Care. 2007 
Apr;30(4):939-45.
17. Yilmaz MI, Carrero JJ, Ortiz A, Martín-Ventura JL, 
Sonmez A, Saglam M, Yaman H, Yenicesu M, Egido J, 
Blanco-Colio LM. Soluble TWEAK plasma levels as a 
novel biomarker of endothelial function in patients with 
chronic kidney disease. Clin J Am Soc Nephrol. 2009 
Nov;4(11):1716-23.
18. Ahmed MS, Wong CF, Pai P. Cardiorenal syndrome: 
a new classification and current evidence on its 
management. Clin Nephrol. 2010 Oct;74(4):245-57.
19. Sarnak MJ. Cardiovascular complications in chronic 
kidney disease. Am J Kidney Dis. 2003 Jun;41(5 
Suppl):11-7. 
20. Levin A. Clinical epidemiology of cardiovascular 
disease in chronic kidney disease prior to dialysis. Semin 
Dial. 2003 Mar-Apr;16(2):101-5.
21. Blanco-Colio LM, Martín-Ventura JL, Muñóz-García 
B, Orbe J, Páramo JA, Michel JB, Ortiz A, Meilhac O, 
Egido J. Identification of soluble tumor necrosis factor-
like weak inducer of apoptosis (sTWEAK) as a possible 
biomarker of subclinical atherosclerosis. Arterioscler 
Thromb Vasc Biol. 2007 Apr;27(4):916-22. 
22. Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, 
Eyileten T, Caglar K, Oguz Y, Vural A, Çakar M, Egido 
J, Altun B, Yenicesu M, Blanco-Colio LM, Carrero JJ. 
Soluble TWEAK and PTX3 in nondialysis CKD patients: 
impact on endothelial dysfunction and cardiovascular 
outcomes. Clin J Am Soc Nephrol. 2011 Apr;6(4):785-
92. 
31
Arab Journal of Nephrology and Transplantation
Hassan, El-demery, Ahmed and Abukhalil Soluble TWEAK and cardiovascular morbidity
Blanco-Colio et al [21] analyzed supernatants obtained 
from cultured human carotid plaques and healthy arteries 
and found that sTWEAK levels were decreased in 
carotid plaque supernatants. Subsequent measurement 
of sTWEAK in plasma showed a reduced concentration 
in subjects with carotid stenosis compared with healthy 
subjects. Furthermore, they found that sTWEAK 
concentrations were negatively correlated with the carotid 
intima-media thickness in asymptomatic subjects, and 
reported that sTWEAK can be an index of subclinical 
atherosclerosis.
Studies are directed towards the discovery of the cause 
of decreased sTWEAK levels as a provoking factor 
of atherogenesis. It was found that in animal models 
the pathologic effects of sTWEAK were mediated by 
the binding with its receptor Fn14. Fn14 expression is 
practically absent in healthy human aortic wall but is 
highly increased under pathologic conditions. A pro-
inflammatory environment increases Fn14 expression, and 
also  allows CD163 to sequester and degrade sTWEAK 
by acting as a scavenger receptor, thus preventing Fn14 
binding [24]. 
On the basis of these explanations we can speculate 
that the reduction in sTWEAK concentrations across 
CKD stages could potentially reflect either of these two 
processes. King [25] reported that administration of 
TWEAK in experimental animals resulted in formation of 
extensive atherosclerotic lesions, which were prevented 
by pretreatment with anti-TWEAK antibody. Muñoz-
García et al [26] also reported that in experimental mice, 
administration of TWEAK aggravated macrophage and 
chemokine expression in atherosclerotic plaques and in 
renal lesions.
A possible explanation of this apparent contradiction is 
that endogenous TWEAK participates in the atherogenic 
process.  Recent data suggest that TWEAK is also a 
ligand for the scavenger receptor, CD163. Differences 
observed between studies could be attributed to TWEAK/
CD163-mediated effects, suggesting that TWEAK may 
mediate some of its effects through receptors other than 
Fn14 [25]. 
Conclusion
Soluble TWEAK levels are significantly lower in CKD 
patients compared to controls. Soluble TWEAK can be 
a novel biomarker of atherosclerosis and endothelial 
dysfunction as well as cardiovascular outcome in CKD 
patients.
Table 2: Laboratory data and carotid intima media thickness (IMT) of studied CKD patients
Variable Group 1 Group 2 Group 3 P value
Total cholesterol (mg/dL) 188±23.5 190.5±28 188.6±33.7 >0.05
Triglycerides (mg/dL) 156.4±13.5 157±13.2 157±11 >0.05
Serum calcium (mg/dL) 9.9±0.5 8.2±0.6 7.2±0.8 <0.01
Serum phosphorus (mg/dL) 4.5±0.4 5.9±0.7 6.8±1.4 <0.01
Serum albumin (g/dL) 3.8±0.2 3.7±0.3 3.9±0.1 >0.05
24 hours urinary proteins (g/day) 1.5±0.5 1.1±0.3 0.7±0.3 <0.01
Hemoglobin (g/dL) 13.5±1.4 11.2±1 8.9±0.9 <0.01
Carotid IMT (mm) 0.5±0.01 0.71±0.06 0.92±0.1 <0.01
Table 3: sTWEAK and IL-6 level in studied CKD patients and controls
Variable Group 1 Group 2 Group 3 Controls P value
sTWEAK(pg/mL) 380.2±50.5 290.6±50.8 160.8±70.8 450±64.4 <0.01
IL-6(pg/mL) 4.2±1.8 7.1±2 11±2.1 2.1±1 <0.01
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